Oxford-based Ultromics, a pioneer in AI-driven cardiology diagnostics solutions, has raised $55 million through its Series C funding round. Ultromics has developed the first FDA-cleared, Medicare-reimbursed AI technology designed to help clinicians detect Heart Failure with Preserved Ejection Fraction (HFpEF) and cardiac amyloidosis, two of the most difficult-to-diagnose forms of heart failure. Built on years of clinical research and analysis of hundreds of thousands of echocardiograms, the plat...